Cholangiocarcinoma

被引:213
作者
Patel, T [1 ]
机构
[1] Texas A&M Univ, Hlth Sci Ctr, Scott & White Clin, Coll Med,Sect Liver Dis, Temple, TX 76508 USA
来源
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2006年 / 3卷 / 01期
关键词
biliary tract malignancy; diagnosis; epidemiology; management; treatment;
D O I
10.1038/ncpgasthep0389
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cholangiocarcinomas are rare malignant tumors composed of cells that resemble those of the biliary tract. On the basis of their anatomic location, cholangiocarcinomas can be classified as intrahepatic, extrahepatic and hilar tumors. For reasons that are not clear, the incidence of cholangiocarcinoma is increasing globally. Established risk factors, including conditions associated with chronic biliary tract inflammation, account for a small proportion of cases. Additional risk factors such as cirrhosis, infection with hepatitis B virus and hepatitis C virus are now becoming recognized. The diagnosis of cholangiocarcinoma requires the integration of clinical information, imaging studies of the hepatic parenchyma and biliary tract, tumor markers, and histology. In terms of the treatment options for cholangiocarcinoma, surgery can be curative, although few patients are candidates for surgery. Palliative biliary decompression can provide symptomatic relief. Advances in MRI and positron-emission tomography scanning, identification of new tumor markers, improved utility of biliary cytology, and the use of photodynamic therapy for adjunct treatment are all expected to enhance the diagnosis, evaluation and management of cholangiocarcinoma.
引用
收藏
页码:33 / 42
页数:10
相关论文
共 71 条
[1]   Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma [J].
Anderson, CD ;
Rice, MH ;
Pinson, W ;
Chapman, WC ;
Chari, RS ;
Delbeke, D .
JOURNAL OF GASTROINTESTINAL SURGERY, 2004, 8 (01) :90-97
[2]   Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis:: A case-control study [J].
Bergquist, A ;
Glaumann, H ;
Persson, B ;
Broomé, U .
HEPATOLOGY, 1998, 27 (02) :311-316
[3]   Photodynamic therapy for cholangiocarcinoma [J].
Berr, F .
SEMINARS IN LIVER DISEASE, 2004, 24 (02) :177-187
[4]   MANAGEMENT STRATEGIES IN RESECTION FOR HILAR CHOLANGIOCARCINOMA [J].
BISMUTH, H ;
NAKACHE, R ;
DIAMOND, T .
ANNALS OF SURGERY, 1992, 215 (01) :31-38
[5]   CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis [J].
Björnsson, E ;
Kilander, A ;
Olsson, R .
LIVER, 1999, 19 (06) :501-508
[6]   Role of US in the detection, characterization, and staging of cholangiocarcinoma [J].
Bloom, CM ;
Langer, B ;
Wilson, SR .
RADIOGRAPHICS, 1999, 19 (05) :1199-1218
[7]   The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis [J].
Boberg, KM ;
Spurkland, A ;
Rocca, G ;
Egeland, T ;
Saarinen, S ;
Mitchell, S ;
Broomé, U ;
Chapman, R ;
Olerup, O ;
Pares, A ;
Rosina, F ;
Schrumpf, E .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2001, 36 (08) :886-890
[8]  
BOND GG, 1990, AM J IND MED, V18, P19
[9]   Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis [J].
Broome, U ;
Olsson, R ;
Loof, L ;
Bodemar, G ;
Hultcrantz, R ;
Danielsson, A ;
Prytz, H ;
SandbergGertzen, H ;
Wallerstedt, S ;
Lindberg, G .
GUT, 1996, 38 (04) :610-615
[10]   Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study [J].
Chalasani, N ;
Baluyut, A ;
Ismail, A ;
Zaman, A ;
Sood, G ;
Ghalib, R ;
McCashland, TM ;
Reddy, KR ;
Zervos, X ;
Anbari, MA ;
Hoen, H .
HEPATOLOGY, 2000, 31 (01) :7-11